EMA Panel Recommends Brexipiprazole for Schizophrenia EMA Panel Recommends Brexipiprazole for Schizophrenia

A European Medicines Agency (EMA) panel has recommended granting marketing authorization for the atypical antipsychotic brexipiprazole for the treatment of schizophrenia.International Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Psychiatry News Alert Source Type: news